Holen Sie sich die Stockscreener-App
94.83
0.02%
-0.02
Handel nachbörslich:
94.95
0.12
+0.13%
Merus N V Aktie (MRUS) Neueste Nachrichten
Why Merus N.V. is moving today2025 Geopolitical Influence & Risk Controlled Daily Trade Plans - newser.com
Will Merus N.V. outperform the marketWeekly Investment Report & Free Reliable Trade Execution Plans - newser.com
Can you recover from losses in Merus N.V.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Will Merus N.V. stock deliver better than expected guidanceQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker - GlobeNewswire Inc.
Merus (MRUS) Shares Promising Interim Findings from Phase 2 Canc - GuruFocus
Merus announces initial interim data from phase 2 trial of petosemtamab - TipRanks
Merus reports promising early data for petosemtamab in colorectal cancer By Investing.com - Investing.com Nigeria
Merus Announces Publication of an Abstract on Petosemtamab - GlobeNewswire
36 patients: Merus' petosemtamab shows preliminary antitumor activity and manageable safety in mCRC phase 2 - Stock Titan
Will Merus N.V. stock continue upward momentumWeekly Investment Report & Fast Gain Stock Tips - newser.com
Can Merus N.V. stock double in next 5 yearsQuarterly Market Review & Free High Return Stock Watch Alerts - newser.com
Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire
Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com Nigeria
Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan
Will Merus N.V. stock sustain high P E ratiosJuly 2025 Weekly Recap & Weekly High Potential Alerts - newser.com
Will Merus N.V. price bounce be sustainable2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com
Deals In Depth: September 2025 - insights.citeline.com
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Truist Securities raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Is Merus N.V. building a consolidation baseQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95 - MarketScreener
MRUS Downgraded to Market Perform by Leerink Partners with Raise - GuruFocus
What MACD signals say about Merus N.V.Profit Target & Consistent Profit Alerts - newser.com
Leerink Partners downgrades Merus stock to Market Perform on Genmab deal - Investing.com
What’s the recovery path for long term holders of Merus N.V.2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stockRecession Risk & Verified Entry Point Detection - newser.com
Relative strength of Merus N.V. in sector analysisJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Will Merus N.V. (2GH) stock maintain strong growth2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):